Gaudium IVF Q4 & FY26 Results: Revenue Jumps 47.56% to ₹10,435.70 Lakhs
Gaudium IVF reported strong financial results for Q4 and FY26. Consolidated revenue surged 47.56% to ₹10,435.70 Lakhs for FY26. PAT from continuing operations grew 27.69% to ₹2,448.85 Lakhs. Standalone revenue increased 21.32% to ₹7,157.85 Lakhs for FY26. The growth was driven by higher patient volumes and improved operational efficiencies.
Substantial revenue and profit growth, especially a nearly 48% increase in consolidated revenue, is a material event for investors and significantly impacts the company's valuation and market perception.
The company has reported significant year-on-year growth in revenue and profit for both consolidated and standalone results, indicating strong business performance and expansion.
Gaudium IVF and Women Health Limited (formerly Gaudium IVF and Women Health Private Limited) has announced its financial results for the quarter and year ended March 31, 2026. The company reported a consolidated revenue from operations of ₹10,435.70 Lakhs for FY26, marking a significant increase of 47.56% compared to ₹7,072.40 Lakhs in FY25. The consolidated EBITDA for FY26 stood at ₹3,770.40 Lakhs, up 31.69% from ₹2,863.07 Lakhs in the previous year. Profit After Tax (PAT) from continuing operations for FY26 was ₹2,448.85 Lakhs, a 27.69% increase from ₹1,917.73 Lakhs in FY25. The company's PAT margin for FY26 was 23.47%.
For the fourth quarter of FY26 (Q4 FY26), consolidated revenue from operations increased by 12.74% to ₹3,035.11 Lakhs from ₹2,692.43 Lakhs in Q4 FY25. Consolidated EBITDA for Q4 FY26 rose by 39.56% to ₹1,217.20 Lakhs. PAT from continuing operations for Q4 FY26 grew by 29.46% to ₹835.74 Lakhs.
On a standalone basis, revenue from operations for FY26 was ₹7,157.85 Lakhs, a 21.32% increase from ₹5,900.16 Lakhs in FY25. Standalone EBITDA for FY26 was ₹3,456.59 Lakhs, up 24.05%. Standalone PAT for FY26 was ₹2,228.77 Lakhs, a 19.61% increase. In Q4 FY26, standalone revenue from operations grew by 31.76% to ₹2,216.60 Lakhs. Standalone EBITDA for Q4 FY26 increased by 35.99% to ₹1,126.15 Lakhs, and standalone PAT saw a 24.51% rise to ₹773.14 Lakhs.
The company highlighted that the consolidated revenue growth was driven by higher patient volumes across mature hubs, supported by strong clinical outcomes, while margins benefited from operating leverage and improved scale efficiencies. The standalone core IVF Treatment business continued to anchor financial performance, supported by strong operating leverage and consistently high clinical success rates.
What to do with a filing like this
Gaudium IVF and Women Health Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gaudium IVF and Women Health Limited. Read the original for the full detail.